In a new Canadian study recently published in the British Medical Journal on the side effects of Actos, it was reported that people being treated for type 2 diabetes with Takeda Pharmaceutical’s drug Actos may be putting themselves at risk for bladder cancer. Lead researcher Laurent Azoulay and her team colleted data on 115,727 patients treated for diabetes from 1988 to 2009, and found that those exposed to the anti-diabetic agent pioglitazone contained in Actos resulted in an 83% higher risk for bladder cancer. Those taking the drug for more than two years are doubling their chances of being diagnosed with the disease. Azoulay and her colleagues ultimately advised “doctors, patients, and regulatory agencies to be aware of the association between the drug and bladder cancer when assessing the overalls risk and benefits of this therapy.” This is not the first time Actos has been linked to bladder cancer. Reservations concerning the drug arose last year when the U.S. FDA and other European regulators required Tadeka Pharmaceuticals to add a warning of the risk of bladder cancer to the drugs label, despite keeping it on the market. Takeda’s failure to adequately warn of the risks of Actos has led to Actos cancer lawsuits being filed around the country.